{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:40:10Z","timestamp":1756276810990,"version":"3.44.0"},"reference-count":32,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Generic name:<\/jats:bold> Naldemedine tosylate<\/jats:p>\n               <jats:p>\n                  <jats:bold>Brand name:<\/jats:bold> Rizmoic<\/jats:p>\n               <jats:p>\n                  <jats:bold>Formulation:<\/jats:bold> 200 mcg film-coated tablets<\/jats:p>\n               <jats:p>\n                  <jats:bold>Market Authorisation holder:<\/jats:bold> Shionogi B.V<\/jats:p>\n               <jats:p>\n                  <jats:bold>Indication:<\/jats:bold> Treatment of opioid-induced constipation in adult patients who have previously been treated with a laxative<\/jats:p>\n               <jats:p>\n                  <jats:bold>Dose:<\/jats:bold> 200 mcg\/day, taken at the same time every day. Naldemedine may be used with or without a laxative. It must be discontinued if treatment with the opioid is discontinued.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Cost:<\/jats:bold> \u00a341.72 for 28 tablets<\/jats:p>\n               <jats:p>\n                  <jats:bold>Classification:<\/jats:bold> Prescription only medicine subject to additional monitoring (\u25bc)<\/jats:p>","DOI":"10.1136\/dtb.2021.000063","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T05:25:40Z","timestamp":1645593940000},"page":"39-43","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Naldemedine for opioid-induced constipation"],"prefix":"10.1136","volume":"60","member":"239","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"2025082622581876000_60.3.39.1","unstructured":"National Institute for Health and Care Excellence . Palliative care for adults: strong opioids for pain relief (CG140) [online], 2016. Available: https:\/\/www.nice.org.uk\/guidance\/cg140 [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003270"},{"key":"2025082622581876000_60.3.39.3","unstructured":"Joint Formulary Committee . British National Formulary [online], 2021. Available: https:\/\/bnf.nice.org.uk\/ [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.4","doi-asserted-by":"publisher","DOI":"10.1186\/ar1782"},{"key":"2025082622581876000_60.3.39.5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S2468-1253(18)30008-6","article-title":"Pathophysiology, diagnosis, and management of opioid-induced constipation","volume":"3","author":"Farmer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025082622581876000_60.3.39.6","doi-asserted-by":"publisher","DOI":"10.1177\/2049463720911986"},{"key":"2025082622581876000_60.3.39.7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"2025082622581876000_60.3.39.8","unstructured":"Rome Foundation . C6 opioid-induced constipation [online], 2016. Available: https:\/\/theromefoundation.org\/rome-iv\/rome-iv-criteria\/ [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","article-title":"Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting \u03bc-opioid receptor antagonists","volume":"36","author":"Argoff","year":"2020","journal-title":"Clin J Pain"},{"key":"2025082622581876000_60.3.39.10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (probe 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med"},{"key":"2025082622581876000_60.3.39.11","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/141737","article-title":"Opioid-induced constipation: pathophysiology, clinical consequences, and management","volume":"2014","author":"Kumar","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"2025082622581876000_60.3.39.12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/pme.12724","article-title":"Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time","volume":"16","author":"Coyne","year":"2015","journal-title":"Pain Med"},{"key":"2025082622581876000_60.3.39.13","first-page":"1837","article-title":"Opioid-induced constipation and bowel dysfunction: a clinical guideline","volume":"18","author":"M\u00fcller-Lissner","year":"2017","journal-title":"Pain Med"},{"key":"2025082622581876000_60.3.39.14","unstructured":"National Institute for Health and Care Excellence . Naldemedine for treating opioid-induced constipation (TA561) [online], 2020. Available: https:\/\/www.nice.org.uk\/guidance\/ta651\/ [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.15","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/169319"},{"key":"2025082622581876000_60.3.39.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3313"},{"key":"2025082622581876000_60.3.39.17","unstructured":"Moventig 25 mg film-coated tablets. Summary of Product Characteristics, GB. Kyowa Kirin Holdings B.V., January 2021."},{"key":"2025082622581876000_60.3.39.18","unstructured":"Relistor 12 mg\/0.6 mL solution for injection. Summary of Product Characteristics, EU. Bausch Health Ireland Limited, December 2019."},{"key":"2025082622581876000_60.3.39.19","unstructured":"Rizmoic 200 micrograms film-coated tablets. Summary of Product Characteristics, EU. Shionogi B.V., January 2020."},{"key":"2025082622581876000_60.3.39.20","unstructured":"European Medicines Agency . Assessment report \u2013 Rizmoic [online], 2018. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rizmoic-epar-public-assessment-report_en.pdf [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025082622581876000_60.3.39.22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster","year":"2018","journal-title":"Pain"},{"key":"2025082622581876000_60.3.39.23","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025082622581876000_60.3.39.24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.281.any","article-title":"Efficacy of naldemedine for the treatment of opioid-induced constipation: a meta-analysis","volume":"28","author":"Esmadi","year":"2019","journal-title":"J Gastrointestin Liver Dis"},{"key":"2025082622581876000_60.3.39.25","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/pm\/pnw325","article-title":"A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"18","author":"Webster","year":"2017","journal-title":"Pain Med"},{"key":"2025082622581876000_60.3.39.26","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025082622581876000_60.3.39.27","first-page":"CD006332","article-title":"Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care","volume":"6","author":"Candy","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082622581876000_60.3.39.28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316001"},{"key":"2025082622581876000_60.3.39.29","unstructured":"Scottish Medicines Consortium . Naldemedine 200 micrograms film-coated tablets (Rizmoic\u00ae) [online], 2020. Available: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/naldemedine-rizmoic-full-smc2242\/ [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.30","unstructured":"OpenPrescribing.net, EBM DataLab, University of Oxford . Search GP prescribing data \u2013 naloxegol [online], 2022. Available: https:\/\/openprescribing.net\/analyse\/#org=CCG&numIds=0106060B0&denom=nothing&selectedTab=summary [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.31","unstructured":"OpenPrescribing.net, EBM DataLab, University of Oxford . Search GP prescribing data \u2013 methylnaltrexone bromide [online], 2022. Available: https:\/\/openprescribing.net\/analyse\/#org=CCG&numIds=0106060A0&denom=nothing&selectedTab=summary [Accessed 1 Feb 2022]."},{"key":"2025082622581876000_60.3.39.32","first-page":"196","article-title":"Naldemedine (Symproic) for opioid-induced constipation","volume":"1535","year":"2017","journal-title":"The Medical Letter"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2021.000063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:58:32Z","timestamp":1756274312000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2021.000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,23]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/dtb.2021.000063"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2021.000063","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2022,2,23]]}}}